Aptorum Group Limited (NASDAQ:APM) Short Interest Down 75.1% in December

by · The Cerbat Gem

Aptorum Group Limited (NASDAQ:APM – Get Free Report) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totaling 2,681 shares, a decline of 75.1% from the December 15th total of 10,748 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 61,744 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 61,744 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company’s shares are short sold.

Aptorum Group Stock Performance

Shares of Aptorum Group stock opened at $1.04 on Tuesday. Aptorum Group has a one year low of $0.69 and a one year high of $4.47. The stock’s 50-day moving average is $1.26 and its 200-day moving average is $1.52.

Analyst Upgrades and Downgrades

APM has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aptorum Group in a research report on Monday, December 22nd. Wall Street Zen raised Aptorum Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 11th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on APM

Aptorum Group Company Profile

(Get Free Report)

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.

Further Reading